- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Trial completion: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Jul 27, 2023
P2/3, N=4044, Completed,
The lack of clinically significant activity may relate to the pharmacokinetics of subcutaneous administration of mAbs. Active, not recruiting --> Completed
- |||||||||| ogalvibart (C-135-LS) / BMS, C144-LS / BMS
Trial completion, Trial completion date: RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers (clinicaltrials.gov) - Aug 4, 2022
P1, N=23, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Feb 2022
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Mar 31, 2022
P2/3, N=4044, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Feb 2022 Recruiting --> Active, not recruiting | N=8797 --> 4044 | Trial completion date: Dec 2023 --> Jun 2023 | Trial primary completion date: Dec 2023 --> Mar 2022
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Enrollment change, Trial completion date, Trial primary completion date: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Aug 23, 2021
P2/3, N=8797, Recruiting,
Recruiting --> Active, not recruiting | N=8797 --> 4044 | Trial completion date: Dec 2023 --> Jun 2023 | Trial primary completion date: Dec 2023 --> Mar 2022 N=2000 --> 8797 | Trial completion date: May 2023 --> Dec 2023 | Trial primary completion date: May 2023 --> Dec 2023
- |||||||||| ogalvibart (C-135-LS) / BMS, C144-LS / BMS
Trial primary completion date: RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers (clinicaltrials.gov) - Jul 8, 2021
P1, N=23, Active, not recruiting,
In conclusion, this study provides proof-of-concept in support of further clinical development of these monoclonal antibodies against COVID-19 during early infection. Trial primary completion date: Jun 2021 --> Mar 2022
- |||||||||| ogalvibart (C-135-LS) / BMS, C144-LS / BMS
Enrollment closed, Enrollment change: RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers (clinicaltrials.gov) - Mar 24, 2021
P1, N=23, Active, not recruiting,
Trial primary completion date: Jun 2021 --> Mar 2022 Recruiting --> Active, not recruiting | N=15 --> 23
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Trial completion date, Trial primary completion date: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Mar 23, 2021
P2/3, N=2000, Recruiting,
Recruiting --> Active, not recruiting | N=15 --> 23 Trial completion date: Dec 2021 --> May 2023 | Trial primary completion date: Dec 2021 --> May 2023
- |||||||||| ogalvibart (C-135-LS) / BMS, C144-LS / BMS
Enrollment open: RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers (clinicaltrials.gov) - Jan 11, 2021
P1, N=15, Recruiting,
Trial completion date: Dec 2021 --> May 2023 | Trial primary completion date: Dec 2021 --> May 2023 Not yet recruiting --> Recruiting
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Trial completion date, Trial primary completion date: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Jan 6, 2021
P2/3, N=2000, Recruiting,
Not yet recruiting --> Recruiting Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Dec 2021
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Trial primary completion date: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Dec 3, 2020
P2/3, N=2000, Recruiting,
Trial completion date: Feb 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Dec 2021 Trial primary completion date: Nov 2020 --> Feb 2021
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
Enrollment open: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Aug 20, 2020
P2/3, N=2000, Recruiting,
Trial primary completion date: Nov 2020 --> Feb 2021 Not yet recruiting --> Recruiting
- |||||||||| bamlanivimab (LY-CoV555) / Eli Lilly, AbCellera, National Institute of Allergy and Infectious Diseases
New P2/3 trial: ACTIV-2: A Study for Outpatients With COVID-19 (clinicaltrials.gov) - Aug 19, 2020
P2/3, N=2000, Not yet recruiting,
|
